Market Overview

Aspergillosis| A Drug Pipeline Analysis Report 2018| Technavio


Technavio has announced their latest drug pipeline analysis report on aspergillosis.
The report includes a detailed analysis of the pipeline molecules under
investigation within the defined data collection period to treat

This press release features multimedia. View the full release here:

Technavio has published a new report on the drug development pipeline for aspergillosis, including a ...

Technavio has published a new report on the drug development pipeline for aspergillosis, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

This report by Technavio
presents a detailed analysis of the market, including regulatory
framework, drug development strategies, recruitment strategies, and key
companies that are expected to play an essential role in the growth of
the market in the future.

This report is available at a USD 1,000 discount for a limited time
market snapshot before purchasing

Aspergillosis: Market overview

Aspergillosis is an infection caused by Aspergillus, a common
mold (a type of fungus) that lives indoors and outdoors. Most people
breathe in Aspergillus spores every day without getting sick.
However, people with weakened immune system or those with lung diseases
are at high risk of developing health problems due to Aspergillus. There
are several kinds of aspergillosis. One kind is allergic
bronchopulmonary aspergillosis (also called ABPA), a condition where
fungus causes allergic respiratory symptoms like asthma, wheezing, and
coughing, but it does not actually invade and destroy tissues. Another
kind of aspergillosis is invasive aspergillosis. This infection usually
affects people with weakened immune system due to cancer, AIDS,
leukemia, organ transplantation, chemotherapy, or other conditions or
events that reduce the number of normal white blood cells.

According to a senior market research analyst at Technavio, "As per
the Centers for Disease Control and Prevention, milder allergic forms of
aspergillosis are more common than the invasive form of the infection.
Invasive aspergillosis is uncommon and occurs primarily in
immunocompromised people."

Aspergillosis: Segmentation analysis

This pipeline analysis report segments the aspergillosis market based on
therapies employed (monotherapy), RoA (oral, oral/intravenous,
inhalation, and intravenous), therapeutic modality (small molecule,
bispecific monoclonal antibody, protein, and peptide), targets
(ergosterol, CYP51A1, beta-(1,3)-D-glucan synthase, and others), MoA
(ergosterol inhibitor, CYP51A1 inhibitor, beta-(1,3)-D-glucan synthase
inhibitor, and others), geographical segmentation (the US, Australia,
Canada, Russia, Japan, and Europe) and recruitment status (completed,
and recruiting). It provides an in-depth analysis of the prominent
factors influencing the market, including drivers, opportunities,
trends, and industry-specific challenges.

Based on therapeutic modality, 85% of the molecules that are being
investigated for the treatment of aspergillosis are small molecules.

Looking for more information on this market? Request
a free sample report

Technavio's sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

  • Drugs under development
  • Indications coverage

Drug Development Strategies

  • Therapies employed
  • RoA
  • Therapeutic modality
  • Geographical coverage

Recruitment Strategies

  • Recruitment status
  • Gender
  • Age

Key Companies

  • Type of players
  • Company overview

Discontinued or Dormant Molecules

About Technavio

is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio's comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team

View Comments and Join the Discussion!